Skip to main content
SpringerLink
Log in

Teriflunomide good value for money in RRMS in Finland

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Funding for the analysis was provided by Genzyme, a Sanofi company, Helsinki, Finland.

Reference

  • Soini E, et al. Cost-Utility Analysis (CUA) of first-line disease-modifying treatments (DMT) Versus Best Supportive Care (BSC) in Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients. 17th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes : (plus poster) abstr. PND52, 8 Nov 2014. Available from: URL: http://www.ispor.org/RESEARCH_STUDY_DIGEST/list.asp?qs=38080.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teriflunomide good value for money in RRMS in Finland. PharmacoEcon Outcomes News 717, 36 (2014). https://doi.org/10.1007/s40274-014-1761-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1761-7

Search

Navigation